You are here

IGF::OT::IGF OTHER FUNCTIONS TOPIC 301, PHARMACO-KINESIS CORPORATION PHASE I ENTITLED A VEGF NANOSENSOR TO MONITOR TUMOR PROGRESSION

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CO120036
Agency Tracking Number: N43CO120036
Amount: $170,009.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5933 W. Century Blvd Suite 1010
Los Angeles, CA 90304-1116
United States
DUNS: 808382795
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARCO CURRELI
 (310) 734-4447
 MARCOCURRELI@GMAIL.COM
Business Contact
 MARCO CURRELI
Phone: (310) 734-4447
Email: MARCOCURRELI@GMAIL.COM
Research Institution
 Stub
Abstract

The overarching goal of this project is to develop and commercialize a nanotechnology-based diagnostic platform capable of monitoring tumor microenvironments in vivo. Specifically, PKC will develop a biosensor based on carbon nanotube transistor technologies for monitoring levels of vascular endothelial growth factor (VEGF) proteins, a general biomarker associated with tumors. In the Phase I stage of the project (this contract research), PKC will first complete the design and fabrication of a prototypenanosensor and then evaluate its performance in detecting various clinically relevant VEGF levels in cerebral spinal fluid (CSF) in vitro. In the upcoming Phase II stage, the nanosensor will be integrated into PKC's Metronomic Biofeedback Pump (MBP) totest its long term performance in detecting VEGF in vivo. Overall, it is expected that the VEGF nanosensor will exploit the great sensitivity of carbon nanotubes to achieve detection of VEGF proteins at the clinically relevant range (10 ~ 10,000 pg/mL in CSF). Upon integration of the VEGF nanosensor into the MBP the levels of this biomarker will be monitored in vivo, in real-time, and for the entire length of the therapy (long term), making personalized medicine a reality. To reach the goals of this Phase I study, a detailed Statement-of-Work (SOW) and a list of major deliverables are provided below.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government